Uveal melanoma expression of indoleamine 2,3-deoxygenase: Establishment of an immune privileged environment by tryptophan depletion
- 25 July 2007
- journal article
- Published by Elsevier in Experimental Eye Research
- Vol. 85 (5), 617-625
- https://doi.org/10.1016/j.exer.2007.07.014
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma PatientsDermatology, 2006
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006
- Cellular and molecular mechanisms of liver toleranceImmunological Reviews, 2006
- 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanismsCytokine, 2006
- Metastatic Uveal Melanoma TherapyInternational Ophthalmology Clinics, 2006
- Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan MetaboliteScience, 2005
- Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-DioxygenaseThe Journal of Experimental Medicine, 2002
- Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic CellsThe Journal of Experimental Medicine, 2002
- Melanomas that develop within the eye inhibit lymphocyte proliferationInternational Journal of Cancer, 1997
- Accessory cell function of human melanoma cells in mitogen-induced T cell proliferationCellular Immunology, 1988